TABLE 4.

Treatment results of BCVA grouped by baseline OCT biomarker status.

	Percentage of eyes with BCVA improvement		Final BCVA response (Δ LogMAR, mean ± SD)
Baseline biomarker	(+)	(–)	(+)	(–)
DRIL	24/51 (47.1%)	9/13 (69.2%)	–0.11 ± 0.43	–0.22 ± 0.21
ERM	19/35 (54.3%)	14/29 (48.3%)	–0.12 ± 0.43	–0.15 ± 0.35
EZD	17/34 (50.0%)	16/30 (53.3%)	–0.20 ± 0.44	–0.06 ± 0.33
HE	24/46 (52.2%)	9/18 (50.0%)	–0.14 ± 0.43	–0.11 ± 0.28
HRF	32/59 (54.2%)	1/5 (20.0%)	–0.15 ± 0.41	–0.00 ± 0.06
IRC	28/53 (52.8%)	5/11 (45.5%)	–0.14 ± 0.43	–0.09 ± 0.16
LONLC	9/20 (45.0%)	24/44 (54.5%)	–0.14 ± 0.52	–0.13 ± 0.33
SRF	6/15 (40.0%)	27/49 (55.1%)	–0.16 ± 0.44	–0.13 ± 0.38
VMI	6/16 (37.5%)	27/48 (56.3%)	–0.09 ± 0.33	–0.15 ± 0.41

Comparing positive baseline biomarker status to negative baseline biomarker status, by Chi-Square and Student t-test.